It is used to treat multiple myeloma, ovarian cancer, AL amyloidosis, and occasionally malignant<unk> anoma. The agent was first investigated as a possible drug for use in<unk> anoma, it was not found to be effective. In 2016, it was approved in the U.S. for: * use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in multiple myeloma (MM) patients * the palliative treatment of MM patients for whom oral therapy is not appropriate<unk>  is currently being used to treat ocular retinoblastoma, a pediatric solid tumor. This is accomplished via transarterial catheter based slow pulsed infusion into the ophthalmic artery.
Melphalan
Ifosfamide
Vincristine
Busulfan
Normustine
Carmustine
Lomustine
Bendamustine